![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
NEW ORLEANS and LONDON, Sept. 16, 2022 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo” or the “Company”), an organization growing therapies that reset the immune system to obtain superior long-term remission for sufferers with autoimmune and allergic illnesses, right now introduced that it is going to be collaborating in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment going down in Basel, Switzerland from September 21-22.
Revolo’s Group Chief Executive Officer, Jonathan Rigby, and Chief Scientific Officer, Dr. Rely Foulkes, will current a company overview on Wednesday, September 21 at 12:00 p.m. CEST (6:00 a.m. EDT). In addition, Dr. Foulkes will be part of an skilled panel dialogue on autoimmune and inflammatory illnesses on Thursday, September 22 at 11:10 a.m. CEST (5:10 a.m. EDT).
The Sachs Associates Biotech in Europe Forum is very transactional and is comprised of a collection of panels and shows from main funding, pharmaceutical and biotech corporations. The full agenda for the discussion board could be accessed right here.
About Revolo Biotherapeutics
Revolo Biotherapeutics is growing therapies that reset the immune system to obtain superior long-term remission for sufferers with autoimmune and allergic illness, with out the immune system suppression seen with present therapies. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system to prevent the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. ‘1805 is a modified analogue of a key protein in immune function preparing to be evaluated in a second Phase 2 clinical trial for moderate-to-severe rheumatoid arthritis and a Phase 2 clinical trial for non-infectious uveitis. ‘1104 is a peptide derived from a natural immune-regulatory protein and is being evaluated in a fully randomized Phase 2 clinical trial for patients with eosinophilic esophagitis (EoE) and a Phase 2 clinical trial for allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutic’s property supplies a possible platform for the growth of therapies for a number of autoimmune and allergic illnesses.
For additional info, please go to www.revolobio.com.
Company Contact
Marylyn Rigby, VP Investor Relations & Marketing
[email protected]
Media Contact
Monica Rouco Molina, Ph.D.
LifeSci Communications
+1-929-469-3850
[email protected]
